Navigation Links
Judge, Jury = Status Quo: Astonishment as Medical Panel Rubber Stamps its Own Controversial Guidelines
Date:4/28/2010

Researchers on the sidelines tell thousands of sufferers that chronic Lyme doesn't exist; no viable alternative explanations given

BETHESDA, Md., April 28 /PRNewswire-USNewswire/ -- Despite years of controversy, an antitrust lawsuit by the Connecticut Attorney General, and nine months of review, the Infectious Diseases Society of America (IDSA) double downed on its own controversial Lyme disease treatment guidelines with a status quo decision critics call "highly suspect."

"It's a sad day for the health care system and for everyone who suffers from the Lyme disease epidemic," says Dr. Robert Bransfield, President of the International Lyme and Associated Diseases Society (ILADS).  "The IDSA's flawed positions means patients will continue to suffer with incorrect diagnosis and improper treatment."  Treatment guidelines are crucial when it comes to healthcare because they may dictate whether patients can get diagnosed and treated for illnesses and whether or not insurance companies will pay for it.  

Connecticut Attorney General Richard Blumenthal launched an investigation against the IDSA citing evidence that the authors of 2006 Lyme disease guidelines had undisclosed conflicts of interest that may have influenced their conclusions. He also charged that they failed to consider differing medical opinions.  This landmark event represented the first ever lawsuit against a professional medical society for guidelines abuse.

The much anticipated verdict just released by a special review panel effectively rubber stamped the association's earlier, contested guidelines.  It limits treatment to three to four weeks of antibiotics. Physicians, Lyme patients and advocacy groups weren't surprised but are dismayed that the panel decided to turn its back on the science - backed by 1300 pages of peer-reviewed articles, that proves Lyme disease can become chronic, debilitating and can be missed due to unreliable testing (as acknowledged by the CDC and FDA).  Hundreds of thousands of patients and their families suffer from chronic Lyme disease.  "By and large, the people on the IDSA panel who made this decision are ivory tower researchers," says Bransfield.  "They're not the doctors on the front lines looking into the eyes and faces of these very sick patients, performing exams and then assuming long term responsibility for dealing with patients suffering from chronic Lyme.

Bransfield and ILADS point to a number of discrepancies and other concerns about the vote, including:

  • 68 out of 69 of the original 2006 recommendation under review were OK'd with unanimous votes. "How can there be such a total consensus with any scientific issue?" asked Bransfield. "It's highly suspect and beyond comprehension."
  • If Lyme cannot be chronic, then why did the guideline's authors acquire 200 Lyme disease patents and receive $76 million in Federal funds to study it?
  • The original guidelines are not only controversial, but written in 2006, are considered old and out of date.
  • The CDC has also advised for many years that the disease should be diagnosed on clinical grounds and not by unreliable laboratory tests. The Lyme disease tests are inaccurate 50% of the time.
  • The IDSA's decision reinforces that doctors have little control when it comes to treating diseases such as Lyme.  Researchers and insurance companies remain in the driver's seat of diagnosis and treatment.

Lyme disease has reached epidemic levels across the United States. While the CDC reports 30,000 new cases a year, it recognizes that number could be as high as 300,000, making it a larger epidemic than AIDS.

Dr. Bransfield says ensuring the integrity of guideline development processes as they were intended to be used is critical to quality health care in the United States.  "Conflicts of interest on guidelines panels are now a crisis," Bransfield says. "It is time for Americans to realize how important the issue of guideline development is.  Patient lives are at stake and no one is being held accountable when guidelines abuse place financial interests above patient care."

www.idsociety.org


'/>"/>
SOURCE International Lyme and Associated Diseases Society
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Announces Further Update Regarding Status of Merck Agreement
2. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
3. World-Leading Alcohol Abuse Lab Status for Trimega
4. Volcano Corporation Announces Litigation Status
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. Frost & Sullivan Award Underlines Cipla Medpros Status as Company of the Year in the South African Generic Pharmaceutical Market
7. OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy
8. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
9. Dynatronics Will Request Hearing With Nasdaq Regarding Listing Status
10. Northern California Cancer Centers First-of-Its-Kind Research Reveals Low Socioeconomic Status Often Equals Poor Chance of Lymphoma Survival
11. Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
Breaking Medicine Technology:
(Date:5/30/2016)... GA (PRWEB) , ... May 30, 2016 , ... ... on June 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training ... Shaolin Institute annual overnight summer camp offers families and children a fun and ...
(Date:5/29/2016)... , ... May 29, 2016 , ... Whole Health Supply ... their new KlipPro KP-240L clipper is available to the public. This is an unusual ... substantially wider than the average clipper. , Everything about this product is concentrated on ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time consuming ... onto their media," said Christina Austin - CEO of Pixel Film Studios. , ... easily add stylish color grades to their footage. A LUT is a Lookup Table ...
(Date:5/28/2016)... ... 2016 , ... In a part of the city where’s it’s easy to spot the neon ... is hoping to attract diners with a taste for real food. , On ... doors to Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with ...
(Date:5/27/2016)... ... ... Two director-level employees of Horizon Blue Cross Blue Shield of New Jersey ... The award recognizes businesswomen who excel in their fields and who have made ... (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, Director ...
Breaking Medicine News(10 mins):